Table 1.

Anti-CTLA-4 treatment overcomes disease antagonism by PLP-Q

Peptide	Antibody	Disease incidence	Mean peak clinical score	Mean day of onset	Mean total foci
PLP-139–151	Control IgG	18/23	1.8  ± 0.4*	11.8  ± 1.5	43.9  ± 10.7
PLP-139–151	Anti-CTLA-4	23/23	2.5  ± 0.5	11.5  ± 1.1	91.3  ± 18.3
5:1 PLPQ:PLP-139–151	Control IgG	8/25†	1.3  ± 0.3‡§	12.4  ± 1.6	19.4  ± 7.0
5:1 PLPQ:PLP-139–151	Anti-CTLA-4	20/25	2.0  ± 0.7	12.5  ± 2.1	38.2  ± 8.5

Data are cumulative from four separate experiments, except mean total foci, which are from two of the four experiments. Mean peak clinical score and day of onset are presented for those animals in which disease occurred (score ≥ 1.0) ± SD. Mean total foci are presented ± SE (n = 13–15 animals per treatment condition). Individual experiments consisted of 5–10 animals per group. 

^*P < 0.0003 compared with PLP-139–151/anti-CTLA-4. 

^† P = 0.0013 compared with coimmunization/anti-CTLA-4. 

^‡ P < 0.0213 compared with coimmunization/anti-CTLA-4. 

^§ P < 0.006 compared with PLP-139–151/control IgG antibody.